(CRIS) Curis, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CRIS) Curis, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Curis, Inc. BCG Matrix is a company-specific framework used to assess the portfolio by comparing market growth and relative market position across Stars, Cash Cows, Question Marks, and Dogs. The page already includes a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
No confirmed star asset
At year-end 2025, Curis, Inc. had 0 approved proprietary products with a high market share, so the Star box was effectively empty.
Its value still came from pipeline assets and partner economics, not from a commercial product franchise.
That means Curis’ upside depended on development progress and deal terms, not on an established star asset.
Emavusertib Phase 1/2
Emavusertib was Curis, Inc.’s lead oral small molecule and stayed in Phase 1/2 through end-2025, so it had no revenue or market share yet. It was being tested in non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes, three high-need blood cancer markets. The target set is attractive, but the asset was still pre-commercial and contributed zero sales.
Fimepinostat clinical-stage
Curis, Inc.’s Fimepinostat stayed clinical-stage and precommercial, so it was not a true Star yet. It was being developed for MYC-altered diffuse large B-cell lymphoma, a high-need oncology niche tied to a disease that makes up about 30% to 40% of non-Hodgkin lymphoma cases. That kept the asset in Curis, Inc.’s high-upside bucket, but without sales it still fit better as a speculative pipeline bet.
CI-8993 early oncology
CI-8993 sat in Curis, Inc.'s Stars box because VISTA is a high-growth immuno-oncology target, but the asset was still early-stage and had no commercial revenue by end-2025. Curis reported no product sales from this program, so its value was tied to pipeline optionality, not cash flow. The market stayed large: global oncology drug sales topped $200 billion in 2025.
- High-growth target: VISTA
- No 2025 commercial share
- Value depended on clinical progress
CA-170 solid tumor program
CA-170 targeted advanced solid tumors and lymphomas, two oncology areas that sit inside a global cancer-drug market of about $250 billion in 2024. Because Curis, Inc. kept the program in development and had not yet proven Phase 3 or commercial value, CA-170 fit better as a potential star than a true BCG star.
- Large markets
- Still developmental
- High upside, no sales
Curis Lacks a True Star Asset in 2025
At year-end 2025, Curis, Inc. had no approved, high-share products, so the Stars box was effectively empty. Its main programs, Emavusertib, Fimepinostat, CI-8993, and CA-170, were still clinical-stage and had zero product sales. So Curis’ upside rested on trial progress, not on a true star asset.
| Program | 2025 status | Star fit |
|---|---|---|
| Emavusertib | Phase 1/2 | No |
| Fimepinostat | Clinical-stage | No |
| CI-8993 | Early-stage | No |
| CA-170 | Developmental | No |
What is included in the product
Detailed Word Document
Curis, Inc. BCG Matrix maps its pipeline and oncology assets into Stars, Cash Cows, Question Marks, and Dogs for capital-allocation insight.
Editable Excel File
One-page Curis, Inc. BCG Matrix for quick quadrant clarity and faster strategy decisions
Reference Sources
Curis, Inc. Reference Sources give decision-makers a credible, traceable trail to verify key assumptions fast.
Cash Cows
Erivedge royalties
Erivedge royalties fit the cash-cow box because Curis’ only clearly marketed, recurring-economics asset is a mature drug, launched in 2012, that Curis commercializes with F. Hoffmann-La Roche and Genentech. In a BCG Matrix, this kind of legacy royalty stream usually means low growth but steady cash generation, which helps fund Curis’ newer pipeline.
Advanced basal cell carcinoma
Erivedge supports Curis, Inc.'s advanced basal cell carcinoma cash cow: it serves a niche, clinically defined population, not a broad growth market. Advanced BCC is a small slice of skin-cancer demand, and Erivedge is used only in adults with metastatic or locally advanced disease, so the revenue base is stable but slow-moving. That makes it a low-growth, mature asset for Curis.
Hedgehog pathway franchise
Erivedge is a hedgehog pathway inhibitor, and its biggest risk is already gone: it cleared discovery, clinical, and approval hurdles years ago. That makes Curis, Inc.’s hedgehog pathway franchise a classic cash cow, where the main job is to keep monetizing an approved asset rather than fund new risk. The question is less about R&D and more about preserving steady royalty and partner-driven revenue from an established brand.
Partnered commercialization model
Curis, Inc. treats Erivedge as a cash cow because Roche and Genentech handle marketing and market access, so Curis avoids the full cost of selling a brand itself. This partnered model keeps support spend light and lets Curis collect economics with less commercial risk. In FY2025, the value driver is still the royalty stream, not a large in-house sales force.
- Low SG&A burden
- Partner runs commercialization
- Royalty income drives cash
Royalty-driven revenue base
Curis, Inc.'s cash cow was its royalty and collaboration revenue, which brought in cash with far less new spending than a fresh drug launch. That model fit the BCG "cash cow" profile because the company could keep harvesting economics from existing assets while limiting incremental capital needs. It was the clearest source of steady cash generation in Curis’ mix.
- Royalty-led cash, low reinvestment
- Collaboration fees supported liquidity
- Best fit for BCG cash cow
Erivedge: Curis’ Cash Cow
Erivedge is Curis, Inc.'s cash cow because it is a mature, approved asset launched in 2012 and monetized through Roche and Genentech. In FY2025, Curis kept a low commercial burden while collecting partner-driven economics from this legacy franchise. That makes it low growth, but still useful for cash.
| Asset | FY2025 role | BCG fit |
|---|---|---|
| Erivedge | Royalty-driven cash | Cash cow |
Preview Before You Purchase
Curis, Inc. Reference Sources
The Curis, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No sample pages or hidden edits—just the full, ready-to-use report in its final format. Once purchased, you’ll get immediate access to the same file for downloading, reviewing, or sharing.
Dogs
No confirmed dog asset
Curis, Inc. did not show a clear dog asset in strict BCG terms. The only meaningful commercial cash source was the Erivedge royalty stream; the rest of the portfolio stayed clinical or preclinical, so there was no separate low-growth, low-share product to label as a dog. In practice, that means Curis had 1 royalty asset, but no disclosed standalone laggard.
No owned commercial launch
Curis, Inc. had 0 self-commercialized oncology brands at end-2025, so there was no weak mature product to label as a classic "dog." The portfolio was still mostly precommercial, with no owned launch to harvest or divest. In BCG terms, this means the "Dogs" bucket was effectively empty, because there was no legacy commercial asset dragging returns.
No large legacy portfolio
In FY2025, Curis, Inc. had no large legacy product portfolio, and the disclosed pipeline stayed narrow. The company did not carry a broad base of old products in slow, mature markets, so there were few true "Dog" assets to classify. That makes the Dogs bucket light, because there is little stagnant revenue to harvest or exit.
No major divestiture block
Curis, Inc. showed no major divestiture block in the asset list, so there was no large noncore commercial unit to harvest as a Dog. That means little near-term cash can come from selling legacy assets; value stayed tied to future readouts and pipeline data.
With no sizable revenue engine to spin off, the Dog label here is weak: there is no obvious $10M+ asset sale or mature franchise to strip out. The risk/reward still depends on clinical milestones, not asset disposals.
- No large noncore unit
- Limited divestiture cash
- Value tied to readouts
Low sales scale overall
Curis stayed an R&D-led biotech in FY2025, with no broad sales engine and no material commercial scale, so cash burn came from research, not a big legacy business. That makes this a scale problem more than a brand problem: the issue was the absence of revenue base, not a weak old product line.
In BCG terms, this fits Dogs only in part, because the business lacked the sales engine that usually traps mature low-growth units. A small or near-zero revenue base means fixed costs matter more, while commercial drag stayed limited.
- FY2025: no broad sales engine
- R&D spend drove cash use
- Main issue was scale, not brand
Curis Had No Dogs to Sell in FY2025
Curis, Inc.'s Dogs bucket was effectively empty in FY2025. The company had no self-commercialized product, no broad legacy franchise, and no disclosed low-share mature asset to harvest or exit. Value still depended on pipeline readouts, not on divesting a weak product.
| FY2025 | Dogs signal | Data point |
|---|---|---|
| Curis, Inc. | None disclosed | 0 owned commercial brands |
| Curis, Inc. | Legacy drag | No mature product base |
| Curis, Inc. | Cash source | Pipeline, not divestiture |
Question Marks
Emavusertib Phase 1/2
Emavusertib was Curis, Inc.'s most advanced growth option in Phase 1/2, with trials in NHL, AML, and MDS. It fit the "question mark" slot because the asset had real upside but still lacked proven efficacy and broad market adoption. That meant Curis, Inc. needed stronger clinical data before Emavusertib could become a real cash driver.
Fimepinostat MYC-altered DLBCL
Fimepinostat targeted MYC-altered diffuse large B-cell lymphoma, a small but high-need niche within a disease that makes up about 30% to 40% of non-Hodgkin lymphoma cases. It stayed a Question Mark in Curis, Inc.’s BCG mix because it had no commercial sales or market share yet, so its value depended on clinical proof, not revenue. In 2025/2026, that meant high upside but very uncertain cash return.
CA-170 advanced tumors
CA-170 targeted advanced solid tumors and lymphomas, both large and active oncology markets with real room for new mechanisms. But Curis still needed stronger clinical data to prove efficacy and lift the asset beyond question-mark status in its BCG mix. Without clearer response and durability signals, CA-170 stayed a high-risk, high-upside program rather than a proven growth driver.
CI-8993 anti-VISTA
CI-8993 anti-VISTA sat in Curis, Inc.'s Question Marks because it aimed at VISTA, a checkpoint-linked immuno-oncology target, in a field that keeps growing but still has a low clinical win rate. The program was early-stage and had no proven market share, so it needed heavy data and capital before it could matter commercially.
- Early asset, high scientific upside
- No proven market share yet
- Depends on future clinical data
CA-327 pre-IND
CA-327 sat in Curis, Inc.'s question mark bucket because it was only in pre-IND, so it was still unproven and far from clinical proof. That stage carries the highest development risk, but it also leaves room for a large payoff if the FDA allows IND filing and early human data are strong. No 2025-2026 clinical readout was available for CA-327, so its value stayed tied to milestone risk.
- Pre-IND: earliest stage
- High upside, highest risk
- No human data yet
Curis’s High-Risk Bets: Big Upside, But No Proof Yet
Curis, Inc.'s Question Marks stayed early-stage, high-upside bets with no proven sales in 2025/2026. Emavusertib, Fimepinostat, CA-170, CI-8993, and CA-327 all depended on clinical proof, not market share, so each could re-rate fast on good data or stay value traps if results stayed weak.
| Asset | Stage | BCG signal |
|---|---|---|
| Emavusertib | Phase 1/2 | High upside, unproven |
| CA-327 | Pre-IND | Highest risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.